9 November 2020 - The NHS could improve patients’ access to new cancer treatments by paying different prices for drugs depending on the disease they are used to treat, concludes a group of experts from across academia and industry.

The consensus panel, representing 16 leading academic institutions, charities, stakeholder groups and pharmaceutical companies, also called for the Government to consider tying prices of drugs to the benefits they deliver for patients.

Read Institute of Cancer Research press release